DMAA, Other Stimulants Cast Shadow Over FDA Supplement Regulation – Study
This article was originally published in The Rose Sheet
Executive Summary
Six workout and weight loss brands contained DMAA and three other stimulants, according to a study in the Journal Clinical Toxicology. Researchers concluded consumers must be informed of risk so they know to check labels for three substances that indicate the presence of the stimulants.
You may also be interested in...
NDI Notifications Take Center Stage In FDA's Evaluation Of DSHEA
FDA's notice for a May 16 public meeting say it intends to ensure its "regulatory framework is flexible enough to adequately evaluate product safety without unnecessarily restricting innovation." But FDA makes clear adherence with its NDI notification requirement is focus of the spurring improvement in VMS product industry's overall compliance with regulatory framework established by DSHEA.
Study Suggests ‘Serious’ Events Are Rare Among All Supplement Adverse Events
Serious adverse events accounted for less than 1% of 41,121 adverse events reported to two supplement firms over 2.5 years, with weight loss agents and products for glycemic management accounting for majority, says a study by regulatory compliance consultants and CRN executives.
Probiotic Safety Latest Target Of Supplement Regulation Critic Cohen
More extensive labeling for probiotics and more stringent GMPs for live microorganism production already are required in Canada, says physician and researcher Pieter Cohen in JAMA Internal Medicine. "Consumers and physicians should not assume that the label on probiotic supplements provides adequate information to determine if consuming the live microorganism is worth the risk," he says.